Camurus AB (FRA:7CA) Cyclically Adjusted Revenue per Share: €1.49 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CA Camurus AB FRA:7CA
83 GF Score
Price €55.45
GF Value €61.13
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Cyclically Adjusted Revenue per Share?

Camurus AB FRA:7CA -1.33% 83 Cyclically Adjusted Revenue per Share is €1.49 as of Jun. 2026. GuruFocus rates FRA:7CA with a GF Score™ of 83/100 and a GF Value™ of €61.13 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Camurus AB's adjusted revenue per share for the three months ended in Jun. 2026 was €1.076. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.49 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Camurus AB's average Cyclically Adjusted Revenue Growth Rate was 25.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-29), Camurus AB's current stock price is €55.45. Camurus AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.49. Camurus AB's Cyclically Adjusted PS Ratio of today is 37.21.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Camurus AB was 68.24. The lowest was 30.22. And the median was 49.89.


Camurus AB  (FRA:7CA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Camurus AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=55.45/1.49
=37.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Camurus AB was 68.24. The lowest was 30.22. And the median was 49.89.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Camurus AB Cyclically Adjusted Revenue per Share Related Terms


Camurus AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Camurus AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB Cyclically Adjusted Revenue per Share Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.86 1.03 1.38

Camurus AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.26 1.38 1.42 1.49

FRA:7CA vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Camurus AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Camurus AB's Cyclically Adjusted PS Ratio falls into.


FRA:7CA
83GF Score
Camurus AB FRA:7CA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Camurus AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.076/134.1100*134.1100
=1.076

Current CPI (Jun. 2026) = 134.1100.

Camurus AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.078 101.138 0.103
201612 0.093 102.022 0.122
201703 0.044 102.022 0.058
201706 0.047 102.752 0.061
201709 0.031 103.279 0.040
201712 0.013 103.793 0.017
201803 0.038 103.962 0.049
201806 0.018 104.875 0.023
201809 0.047 105.679 0.060
201812 0.015 105.912 0.019
201903 0.041 105.886 0.052
201906 0.021 106.742 0.026
201909 0.075 107.214 0.094
201912 0.066 107.766 0.082
202003 0.085 106.563 0.107
202006 0.144 107.498 0.180
202009 0.173 107.635 0.216
202012 0.186 108.296 0.230
202103 0.222 108.360 0.275
202106 0.244 108.928 0.300
202109 0.267 110.338 0.325
202112 0.314 112.486 0.374
202203 0.369 114.825 0.431
202206 0.375 118.384 0.425
202209 0.387 122.296 0.424
202212 0.423 126.365 0.449
202303 0.440 127.042 0.464
202306 1.005 129.407 1.042
202309 0.565 130.224 0.582
202312 0.583 131.912 0.593
202403 0.583 132.205 0.591
202406 0.662 132.716 0.669
202409 0.705 132.304 0.715
202412 0.802 132.987 0.809
202503 0.854 132.825 0.862
202506 1.030 133.699 1.033
202509 0.855 133.480 0.859
202512 0.708 133.390 0.712
202603 0.827 133.560 0.830
202606 1.076 134.110 1.076

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.49 mean?
Camurus AB (FRA:7CA) has a Cyclically Adjusted Revenue per Share of €1.49 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Camurus AB and its competitors.
Is Camurus AB's Cyclically Adjusted Revenue per Share too high?
Camurus AB's current Cyclically Adjusted Revenue per Share is €1.49. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Camurus AB's Cyclically Adjusted Revenue per Share of €1.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Camurus AB and its competitors. Camurus AB's current Cyclically Adjusted Revenue per Share is €1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (FRA:7CA) is currently considered Fairly Valued. The stock's GF Value™ is €61.13, compared to a current price of €55.45 — trading 9.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.49. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Camurus AB (FRA:7CA), the current Cyclically Adjusted Revenue per Share is €1.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (FRA:7CA) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of €55.45 is trading 9.3% below its estimated GF Value™ of €61.13. GuruFocus considers Camurus AB to be Fairly Valued.

Key valuation signals for FRA:7CA:

  • Cyclically Adjusted Revenue per Share: €1.49
  • GF Value™: €61.13 vs. price of €55.45 (9.3% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the FRA:7CA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score

Get the complete analysis for FRA:7CA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.45
Price
€61.13
GF Value